Fractyl Health Reports Q3 2026 Results with Improved Net Loss and Positive REMAIN-1 Clinical Data
Fractyl Health (GUTS) reported a net loss of $14.2 million for the third quarter of 2026, a significant improvement from the previous year driven by reduced operating expenses and favorable changes in warrant liability fair value. The company is undergoing a strategic pivot to focus exclusively on its Revita program, which included a 45% workforce reduction and a target to reduce quarterly operating cash spending by 50% by mid-2027. Clinical results from the REMAIN-1 pivotal study showed strong efficacy for the Revita program, with participants maintaining 80% of tirzepatide-induced weight loss at six months. The data demonstrated a dose-dependent effect and met primary endpoints with statistical significance (p=0.0023). Management is positioning the company to capture the market of patients discontinuing GLP-1 therapies, targeting an initial launch across 30 to 50 specialized bariatric centers.
Topics: adjusted ebitda cash runway clinical trial results net loss operating expenses
Read the full article at Motley Fool
Part of the story Fractyl Health Reports Q3 2026 Results with Improved Net Loss and Positive REMAIN-1 Clinical Data (4 articles)